According to the targeted NGS analysis of tumor samples with pre- and post-cetuximab treatment, the copy number of the SMAD4 gene changed, while the TGF-β signaling pathway had various recurrent mutations [211]. This evidence concerns the gene TGFB1 and neoplasm.